Navigation Links
Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
Date:3/11/2008

sels with excellent

specificity. The high degree of selective targeting seen in the study

provides additional evidence of bavituximab's therapeutic potential.

Bavituximab Anti-Viral Program: During the third quarter, the company continued to advance its bavituximab HCV program and presented positive data at a key liver disease meeting.
-- Added The Johns Hopkins Hospital and a private clinic in Orange

County, California as additional clinical study sites for the HCV/HIV

co-infection study.

-- Presented final results from the Phase I multiple dose HCV trial at

the prestigious Annual Meeting of the American Association for the

Study of Liver Disease that showed bavituximab was well tolerated and

demonstrated encouraging signs of anti-viral activity.

Cotara(R) Glioblastoma Program: Peregrine continued to advance the Cotara brain cancer program.
-- Added additional study sites and continued patient dosing and

follow-up in the Cotara Phase II study in patients with glioblastoma

multiforme, the most deadly form of brain cancer. Eight sites are now

open for patient enrollment.

-- Added an additional site, the Barrow Neurological Institute (BNI) in

Phoenix, Arizona, to the ongoing Cotara dosimetry and dose

confirmation clinical study. BNI also participated in a previous

Cotara Phase II clinical trial.

-- Announced positive results from the first cohort of patients treated

in the Cotara dosimetry trial and from the initial patients treated in

the Cotara Phase II trial. Cotara appeared safe and well tolerated

with no dose-limiting adverse events, with continuing patients being

monitored for overall survival. Several patients in these studies

have lived longer than the six-month expected median survival time for

this patient po
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Peregrine Pharmaceuticals to Announce Third Quarter FY 2008 Financial Results
2. Publication in Clinical Cancer Research Confirms Ability of Peregrines Bavituximab to Target Tumor Blood Vessels with Excellent Specificity
3. Peregrine Pharmaceuticals Doses First Patient in Phase II Clinical Trial of Bavituximab in Patients With Advanced Breast Cancer
4. Peregrine Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
5. Peregrine Pharmaceuticals Remains on Track to Advance its Three Lead Clinical Programs in 2008
6. Defense Threat Reduction Agency Halts Contract Negotiations With Peregrine Pharmaceuticals as It Suffers $100 Million Cut in FY 2008 Budget for Its Transformational Medical Technologies Initiative (TMTI) Program
7. Peregrine Pharmaceuticals to Announce Second Quarter FY 2008 Financial Results
8. New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrines Anti-PS Technology Platform
9. Peregrine Pharmaceuticals to Announce First Quarter FY 2008 Financial Results
10. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
11. Alseres Pharmaceuticals Presents Inosine and Dopamine Transporter (DAT) Blocker Preclinical Data at the American Society for Experimental NeuroTherapeutics (ASENT) Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... Bound Brook, NJ (PRWEB) July 24, 2014 ... expects to manage numerous projects in the MENA region ... delighted to have a preferred provider agreement with DZS ... in the MENA region,” said Global VP of R&D ... "DZS has developed excellent operational practices with a ...
(Date:7/23/2014)...  Sangamo BioSciences, Inc. (NASDAQ: SGMO ) ... accomplishments. For the second quarter ended ... of $7.0 million, or $0.10 per share, compared to ... share, for the same period in 2013. As of ... marketable securities and interest receivable of $236.7 million. ...
(Date:7/23/2014)... ANGELES , July 23, 2014 /PRNewswire-iReach/ -- Think ... cognitive performance for the long term. They are the ... edge of sustained energy as an alternative to the ... Think Drinks on Indiegogo on July 29, 2014, with ... 30-day campaign. Photo - http://photos.prnewswire.com/prnh/20140723/129697 ...
(Date:7/23/2014)... 2014  Having the right people at the table ... business growth and achieving clinical and operational goals. The ... Summit, July 20-22, 2014, in San Diego ... and healthcare experts discussing how partnerships have positively impacted ... & Chief Executive Officer of Cape Regional Medical Center ...
Breaking Biology Technology:SBI Pharmaceuticals Co. Ltd. Enters into Preferred Provider Agreement with DZS Clinical Services 2Sangamo BioSciences Reports Second Quarter 2014 Financial Results 2Sangamo BioSciences Reports Second Quarter 2014 Financial Results 3Sangamo BioSciences Reports Second Quarter 2014 Financial Results 4Sangamo BioSciences Reports Second Quarter 2014 Financial Results 5Sangamo BioSciences Reports Second Quarter 2014 Financial Results 6Sangamo BioSciences Reports Second Quarter 2014 Financial Results 7Sangamo BioSciences Reports Second Quarter 2014 Financial Results 8Sangamo BioSciences Reports Second Quarter 2014 Financial Results 9truBrain Neuroscientists To Launch More Effective, Healthier Alternative To Energy Drinks On Indiegogo 2MSC and Cape Regional Medical Center Partner to Improve Cost, Quality and Outcomes 2
... Optimal for Expansion in Medical Imaging Management , ... BIRMINGHAM, Ala., June 4 Optimal Reading Services Group, ... services for hospitals, imaging centers and radiology groups, announced ... made a substantial investment in Optimal. The investment provides ...
... 4 Ratcliff promoted Jorge Burbano to senior associate and ... this month. The award-winning firm ( http://www.ratcliffarch.com ... design and planning services to healthcare, academic and civic clients ... LEED(R) AP, has more than 20 years of architectural design ...
... , , SAN DIEGO, June 4 Neurocrine ... Kevin Gorman, President and Chief Executive Officer of Neurocrine Biosciences ... Conference in New York. , , The live ... Eastern Time (ET)/10:30 a.m. Pacific Time (PT). The presentation ...
Cached Biology Technology:Optimal Reading Services Group, Inc. Receives Investment from Health Evolution Partners 2Optimal Reading Services Group, Inc. Receives Investment from Health Evolution Partners 3Ratcliff Promotes Jorge Burbano to Senior Associate; Tess Kavanagh and Tony Keung to Associate 2Neurocrine Biosciences to Present at the 8th Annual Needham Life Sciences Conference 2
(Date:7/24/2014)... NEW BRUNSWICK, N.J. A yearlong study funded by ... at the Edward J. Bloustein School of Planning and ... property owners in Sandy-affected towns are skeptical about the ... 400 online survey respondents, 45 percent indicated they were ... town affected by Superstorm Sandy would be rebuilt better ...
(Date:7/24/2014)... is available in German . ... 300 million asthma sufferers worldwide, a further 600 million ... of the global population contending with allergic rhinitis (allergic ... also affect other organs and parts of the body ... intestine (in the form of inflammatory bowel diseases such ...
(Date:7/24/2014)... July 24, 2014 NXT-ID, Inc., (NXTD: OTCQB) a biometric ... its next generation smart wallet, Wocket™, was recently the topic of  ... interviewed Gino Pereira , CEO of NXT-ID, ... Mr. Gino Pereira explains ... of credit cards and walks host Anita Finley ...
Breaking Biology News(10 mins):Rutgers study explores attitudes, preferences toward post-Sandy rebuilding 2New drugs to combat asthma and the like 2New drugs to combat asthma and the like 3Boomer Times Gets to Know NXT-ID's Next Generation Wocket Smart Wallet; Practical, Secure and Easy to Use 2Boomer Times Gets to Know NXT-ID's Next Generation Wocket Smart Wallet; Practical, Secure and Easy to Use 3Boomer Times Gets to Know NXT-ID's Next Generation Wocket Smart Wallet; Practical, Secure and Easy to Use 4
... Scientists (AAPS) is a professional, scientific society of ... and other research institutes worldwide. Founded in 1986, ... exchange of knowledge among scientists to enhance their ... programs, on-going education, information resources, opportunities for networking, ...
... has to work 17 times harder to catch the same amount ... were powered by sail, according to new research. Researchers from ... UK Government data on the amount of fish caught and the ... to analyse the change in fish stocks since 1889. ...
... An experienced fruit fly researcher can tell at a glance ... distinct pigmentation pattern on a fly,s body (a type of bristle ... genitalia are dead giveaways. But most of the fly,s body parts ... no idea whether "maleness" or "femaleness" extended to all of the ...
Cached Biology News:Fishing fleet working 17 times harder than in 1880s to make same catch 2Male or female? In flies, some cells can't tell 2Male or female? In flies, some cells can't tell 3
2,4,6-Trinitrophenyl hapten is conjugated to Bovine Serum Albumin protein through lysine by amide bonds....
EoProbe Eosinophil Staining Kit, 1 Kit...
B.D. Hames and D.M. Glover (1996) • This issue covers T-Cell antigen receptor genes; T-Lymphocyte signal transduction; B-Cell activation antibody engineering and the complement system and other ...
...
Biology Products: